Impact of Second Primary Malignancy Post-Autologous Transplantation on Outcomes of Multiple Myeloma: A CIBMTR Analysis
Autor: | Brittany Knick Ragon, Mithun Vinod Shah, Anita D'Souza, Noel Estrada-Merly, Lohith Gowda, Gemlyn George, marcos DeLima, Shahrukh Hashmi, Mohamed A Kharfan-Dabaja, Navneet S Majhail, Rahul Banerjee, Ayman Saad, Gerhard C. Hildebrandt, Hira Mian, Muhammad Bilal Abid, Minoo Battiwalla, Lazaros J. Lekakis, Sagar S. Patel, Hemant S. Murthy, Yago Nieto, Christopher S Strouse, Sherif M. Badawy, Samer AI Al Hadidi, Bhagirathbhai Dholaria, Mahmoud Aljurf, David H Vesole, Cindy H Lee, Attaphol Pawarode, Usama Gergis, Kevin Charles Miller, Leona A Holmberg, Aimaz Afrough, Melhem M Solh, Pashna Munshi, Taiga Nishihori, Larry D. Anderson, Baldeep Wirk, Gurbakhash Kaur, Muzaffar H Qazilbash, Nina Shah, Shaji K Kumar, Saad Z. Usmani |
---|---|
Rok vydání: | 2023 |
Předmět: | |
Zdroj: | Blood Advances. |
ISSN: | 2473-9537 2473-9529 |
DOI: | 10.1182/bloodadvances.2022009138 |
Popis: | The overall survival (OS) has improved significantly in multiple myeloma (MM) over the last decade with use of proteasome inhibitor and immunomodulatory drug-based combinations, followed by high-dose melphalan and autologous hematopoietic stem cell transplantation (auto-HSCT) and subsequent maintenance therapies in eligible newly diagnosed patients. However, clinical trials employing auto-HSCT followed by lenalidomide maintenance have shown an increased risk of second primary malignancies (SPM), including second hematological malignancies (SHM). We evaluated the impact of SPM and SHM on progression-free survival (PFS) and OS in MM patients following auto-HSCT using CIBMTR registry data. Adult MM patients who underwent first auto-HSCT in the United States with melphalan conditioning regimen from 2011 to 2018 and received maintenance therapy were included (n=3,948). At a median follow up of 37 months, 175 (4%) patients developed SPM, including 112 (64%) solid, 36 (20%) myeloid, 24 (14%) SHM, not otherwise specified, and 3 (2%) lymphoid malignancies. Multivariate analysis demonstrated that SPM and SHM were associated with an inferior PFS (HR 2.62, P |
Databáze: | OpenAIRE |
Externí odkaz: |